oder the Panemork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | Substitute for form 1449/PTO | | Complete if Known | | |
|--|------------------------------|----|-------------------|------------------------|-----------------|
| | | | | Application Number | 09780035 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Filing Date | 2001-02-09 |
| | | | | First Named Inventor | Tariq Ghayur |
| | | | | Art Unit | 1644 |
| (ose as many sneets as necessary) | | | occodery) | Examiner Name | Gambel, Phillip |
| Sheet | | of | | Attorney Docket Number | BBC-084/US |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|----|---|----------------|
| Examiner Initials* | | | T ² |
| | 61 | TAYLOR, LISA D. et al., A transgenic mouse that expresses a diversity of human sequence heavy and light chain immun, Nucleic Acids Research (1992), Vol. 20(23), pgs. 6287-6295 | |
| | 62 | TISSI, LUCIANA et al., Role of Tumor Necrosis Factor Alpha, Interleukin-1B and Interleukin-6 in a mouse model of Group B, Infection and Immunity (1999), Vol. 67; 4545-4550 | |
| | 63 | TRENTHAM, DAVID E. et al., Autoimmunity to Type II Collage: An Experimental Model of Arthritis, Journal of Exp. Med. (1977) Vol. 146, pgs. 857-868 | |
| | 64 | TSUTSUI, HIROKO et al, Caspase-1 Independent, Fas/Fas/ Ligand-Mediated IL-18 Secretion from Macrophages Cases Acute liver injury in Mice, Immunity (1999) Vol. 11, pgs. 359-367 | |
| | 65 | TSUTSUI, HIROKO et al., IL-18 Accounts for both TNF-a- and Fas Ligand-Mediated Hpatotoxic Pathways, Jour. of Immun., (1997), Vol. 159(8) pgs. 3961-3967 | |
| | 66 | URLAUB GAIL et al., Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity, Pro. Natl. Acad. Sci. (1980) Vol. 77(7), pgs. 4216-4220 | |
| | 67 | USHIO SHIMPEI et al., Cloning of the cDNA for Human IFN-y-Inducing Factor, Expression in Escherichia coli, Journal of Immunology (1996) Vol. 156, pgs. 4274-4279 | |
| | 68 | VAN NOSTRAND, WILLIAM E. et al., Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid B-protein precursor, Nature (1989) Vol. 341, pgs. 546-551 | |
| | 69 | WILDBAUM, GIZI et al., Neutralizing Antibodies to IF-y-inducing Factor Prevent Experimental Autoimmune Encaphalomyelitis, Journ. of Immun. (1998) Vol. 161(11), pgs. 6368-6374 | |
| | 70 | WINTER, GREG et al., Making Antibodies by Phage Display Technology, Annua. Rev. of Immun. (1994), Vol. 12, pgs. 433-455 | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for deducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: